Clarification on the effectiveness of Cortrak in reducing pneumothorax risk

Re: Erratum

In response to the Erratum, the following additional clarifying information is provided with reference to the articles previously published in BJN, which are cited in the Erratum below, by the clinical and scientific experts at Avanos Medical (Alpharetta, GA), manufacturers of the Cortrak* 2 Enteral Access System (EAS) for electromagnetic tracking of feeding tubes during placement.

Currently, there is not a device that can totally eliminate pneumothorax risk. However, clinical studies have consistently shown that Cortrak* reduces the incidence of pulmonary complications when used according to its labelling and with appropriate training (Krenitsky, 2011; McCutcheon, 2018; Bourgault, 2020). Statistics provided by the same group of authors as the publications under discussion here, including Taylor et al (2019), support the benefits of using the Cortrak system as a placement guidance tool, relative to blind placement.